U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07678827) titled 'A Phase 3 Bridging Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD' on June 25.
Brief Summary: This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder (ADHD). Eligible participants will be randomized in a 1:1 ratio to receive AK-D101 or placebo once daily for 8 weeks. Randomization will be stratified by study site and age group (children aged 6 to ...